Jeena Sikho Lifecare Limited
Jeena Sikho Lifecare Limited (JSLL) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
jeenasikho.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Sales | 75 Cr | 174 Cr | 190 Cr | 222 Cr | 216 Cr | 224 Cr |
| Operating expenses (approx.) | 66 Cr | 96 Cr | 98 Cr | 121 Cr | 138 Cr | 132 Cr |
| EBITDA | 9 Cr | 79 Cr | 92 Cr | 101 Cr | 78 Cr | 92 Cr |
| OPM % | 12.0% | 45.2% | 48.5% | 45.4% | 36.1% | 41.0% |
| Other income | 0.28 Cr | 1 Cr | 1 Cr | 3 Cr | 3 Cr | 14 Cr |
| Interest | 0.51 Cr | 2 Cr | 4 Cr | 3 Cr | 4 Cr | 3 Cr |
| Depreciation | 2 Cr | 10 Cr | 10 Cr | 11 Cr | 16 Cr | 15 Cr |
| Profit before tax | 7 Cr | 69 Cr | 79 Cr | 89 Cr | 61 Cr | 88 Cr |
| Tax % | 25.9% | 25.2% | 25.4% | 25.1% | 26.4% | 24.7% |
| Net profit | 5 Cr | 51 Cr | 59 Cr | 67 Cr | 45 Cr | 66 Cr |
| EPS (₹) | ₹4.96 | ₹4.13 | ₹4.73 | ₹5.36 | ₹3.63 | ₹5.30 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 147 Cr | 469 Cr | 801 Cr | Sign in for TTM |
| Operating expenses (approx.) | 129 Cr | 344 Cr | 452 Cr | Sign in for TTM |
| EBITDA | 18 Cr | 125 Cr | 349 Cr | Sign in for TTM |
| OPM % | 12.3% | 26.6% | 43.6% | Sign in for TTM |
| Other income | 1 Cr | 6 Cr | 8 Cr | Sign in for TTM |
| Interest | 1 Cr | 0.51 Cr | 13 Cr | Sign in for TTM |
| Depreciation | 3 Cr | 9 Cr | 48 Cr | Sign in for TTM |
| Profit before tax | 15 Cr | 122 Cr | 297 Cr | Sign in for TTM |
| Tax % | 25.8% | 25.7% | 25.5% | Sign in for TTM |
| Net profit | 11 Cr | 91 Cr | 222 Cr | Sign in for TTM |
| EPS (₹) | ₹11.11 | ₹36.50 | ₹17.84 | Sign in for TTM |
| Dividend payout % | 0.0% | 11.4% | 6.2% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 10 Cr | 25 Cr | 25 Cr |
| Reserves | 26 Cr | 167 Cr | 442 Cr |
| Borrowings | 7 Cr | — | 0.45 Cr |
| Other liabilities | 18 Cr | 136 Cr | 207 Cr |
| Total liabilities | 62 Cr | 328 Cr | 674 Cr |
| Fixed assets (net) | 28 Cr | 92 Cr | 118 Cr |
| CWIP | 5 Cr | — | 2 Cr |
| Investments | 0 Cr | 4 Cr | 110 Cr |
| Loans & advances | 3 Cr | — | 0 Cr |
| Inventories | 6 Cr | 12 Cr | 20 Cr |
| Trade receivables | 9 Cr | 98 Cr | 70 Cr |
| Cash & bank | 3 Cr | 26 Cr | 16 Cr |
| Other assets | 7 Cr | 97 Cr | 338 Cr |
| Total assets | 62 Cr | 328 Cr | 674 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 16 Cr | 69 Cr | 254 Cr |
| Cash from investing | -18 Cr | -70 Cr | -202 Cr |
| Cash from financing | -5 Cr | -0.69 Cr | -59 Cr |
| Net cash flow | -6 Cr | -2 Cr | -7 Cr |
| Free cash flow (OCF − Capex) | -0.73 Cr | 27 Cr | 220 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 37.0% | 63.8% | 66.4% |
| ROE % | 30.8% | 47.2% | 47.5% |
| Debtor days | 22 | 76 | 32 |
| Inventory days | 16 | 9 | 9 |
| Days payable | 12 | 7 | 11 |
| Cash conversion cycle | 27 | 77 | 30 |
| Debt / equity | 0.20 | — | 0.0010 |
| Current ratio | 0.90 | 2.91 | 3.25 |
| Net debt / EBITDA | 0.27 | -0.21 | -0.05 |
Compare with peers
Loading peers…